Pancreatic Cancer, Research and Clinical Trials

Meet the investigator: Daniel D. Billadeau, Ph.D.

By Nicole Ferrara • December 11, 2019
Estimated reading time: 1 minute

At the Mayo Clinic Cancer Center, hundreds of researchers dedicate their professional lives to reducing the burden of cancer. Each one has a unique story. In this issue, Daniel D. Billadeau, Ph.D., an oncology researcher at Mayo Clinic in Rochester, Minnesota, talks about his work investigating pancreatic cancer. Dr. Billadeau is also a principal investigator of the Mayo Clinic Pancreatic Cancer SPORE.

Related

This article was originally published in Forefront, Mayo Clinic Cancer Center's online magazine, which ceased publication in December 2020.

cancer pancreatic cancer Pancreatic Cancer research Research and Clinical Trials SPORE
Subscribe
Request an Appointment
Find a Clinical Trial
Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer

The presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of spread and worse survival rates for people with pancreatic cancer.

Beyond the Code: Advancing early pancreatic cancer diagnoses

Mayo Clinic pancreatic cancer experts highlight the importance of early diagnosis and the role of artificial intelligence in transforming patient outcomes.

Researchers resolve uncertainty in BRCA2 testing, improving cancer risk assessment and patient care

Findings will help identify patients with breast, ovarian, pancreatic or prostate cancer who may benefit from targeted therapies.